JPRN-UMIN000013122已完成2 期
A randomized phase II study of the efficacy and safety of combination of Bevacizumab/Pemetrexed versus Pemetrexed maintenance therapy in First-Line treatment of elderly patients with advanced or recurrent post-operative non-squamous and non-small cell lung cancer who received Bevacizumab / Pemetrexed induction therapy. - A randomized phase II study of Bevacizumab/Pemetrexed versus Pemetrexed maintenance therapy in elderly NSCLC who received Bevacizumab / Pemetrexed induction therapy.
Department of Pulmonary Medicine, School of Medicine, Keio University, Tokyo, Japan0 个研究点目标入组 40 人开始时间: 2014年2月10日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 75years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Patients with symptomatic Brain metastasis 2)History of hemoptysis 3)History of thoracic radiotherapy 4)active infection 5)fever 6)severe complication 7)massive pleural effusion or ascites 8)active concomitant malignancy 9)history of severe drug allergy 10)uncontrolled peptic ulcer 11)Current or previous history of GI perforation 12)Patients with therapeutic anticoagulopathy 13)those judged not suitable by the attending physician
研究者
相似试验
进行中（未招募）
1 期
A Phase 2 Randomized Study of the Efficacy and Safety of Acalabrutinib with Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID-19Subjects with life-threatening COVID-19 symptomsMedDRA version: 20.0Level: LLTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 100000004862EUCTR2020-001644-25-FRAcerta Pharma B.V.428
招募中
2 期
A randomized phase II study to evaluate efficacy of negative pressure wound therapy on prophylaxis of the incisional hernia after reversal of temporaly diverting stomatemporally diverting stoma to be planned to have closedJPRN-UMIN000030936Aichi Medical University70
进行中（未招募）
2 期
Efficacy and safety of polyglycolic acid sheet for the prevention of infectious complication after laparoscopic surgery for gastric cancerIntraperitoneal infectious complicationsPostoperative ComplicationsJPRN-jRCTs052210188Obama Kazutaka210
进行中（未招募）
1 期
Evaluation of 2nd or 3rd line treatment by Nivolumab monotherapy or Nivolumab plus Ipilimumab, for unresectable Mesothelioma patientsMalignant Pleural MesotheliomaEUCTR2015-004475-75-FRIFCT114
进行中（未招募）
1 期
A randomized study to explore the efficacy and feasibility of rotations between sunitinib and everolimus versus sequential treatment of sunitinib and everolimus until progression in patients with renal cancer.EUCTR2012-001337-13-ESAPRO115